Home Authors Posts by Dr. Marie Gabrielle Laguna

Dr. Marie Gabrielle Laguna

756 POSTS 0 COMMENTS

Medical doctor-internist

https://www.eternusglobal.com

Dietary Supplement DHA Prevents Preterm Births

Dec 18, 2016

1854

Analyses of two medical trials, one within the U.S. and the other within Australia, advocate that hundreds of thousands of early preterm births, which are those at or earlier than 34 weeks’ gestation, would be avoided if pregnant women took acid (DHA) dietary supplements every day.

The studies wherein pregnant women took DHA dietary supplements everyday independently found statistically significant reductions in early preterm delivery.

DHA and Preterm Birth

The researchers examined low-, moderate- and high-risk births from moms who took DHA supplements in the course of being pregnant in comparison with placebo controls. They estimated that more than 106,000 high-risk early preterm births could be avoided in the U.S. and about 1,100 would be prevented in Australia every year if pregnant women only took omega fatty acid supplements every day.

Babies who were born very preterm in most cases require lifesaving cures and longer hospitalizations at the beginning of life and are at increased risk for extra hospitalizations within the first year of life especially in the developed world. Furthermore, these toddlers are at risk for serious disability or death the earlier they’re born. This is according to Susan Carlson, A.J. Rice Professor of Nutrition at the University of Kansas Medical Center, who co-directed the U.S. study with John Colombo, KU professor of psychology and director of the Life Span Institute.

According to her, At present there is no effective method to prevent spontaneous early preterm birth. Our recent studies suggest that DHA could be a promising agent for reducing this critical public health problem.�

Scientific Studies

The KUDOS (Kansas DHA Outcome Study), headed by Carlson and Colombo, and the DOMinO (DHA to Optimize Mother Infant Outcome) study directed by Maria Makrides, professor of human nutrition and the leader for Healthy Mothers, Babies and Children South Australian Health & Medical Research Institute, as well as Robert Gibson, professor of functional food science at the University of Adelaide, found out that there is a small increase in gestation size. However, this increase was noted to be related to a decrease in deliveries which are at danger for early preterm birth.

DHA (docosahexaenoic acid) is present naturally in cell membranes and are abundant in brain cells, but levels can also be improved by diet or supplements. A baby obtains DHA from his or her mom in utero and postnatally from human milk, however the amount obtained relies on the mother’s DHA levels, Carlson said. According to her, U.S. women typically consume less DHA than women in most of the developed world. The intake of DHA is both the U.S. and Australia is well below that reported by Japanese women.�

By utilising the results of DOMinO and KUDOS, the researchers in both reviews observed that early preterm births could be decreased to just 1.3 percentage in Australia or 1.5 percentage of births in the U.S. in demographically identical populations. Carlson remarked, These percentages are remarkably similar and may reflect the lowest rate of spontaneous early preterm birth that can be achieved in any population�.

Cold Medicine Flufenamic Acid Stops Cancer Metastasis

Dec 16, 2016

1622

A nonsteroid anti-inflammatory drug used for treating colds, flufenamic acid, suppresses the spread of bladder cancers and reduces their chemoresistance in mice, raising hopes of a future cure for evolved bladder cancers, says the researchers.

Researchers from Hokkaido University have discovered that a nonsteroid anti-inflammatory drug for treating colds stops the spread of bladder cancers and decreases their chemoresistance in mice, thus it may be considered in the future as potential therapy for advanced bladder cancers.

Bladder Cancer

Bladder cancer is said to be the seventh most common cancer among males worldwide. Every year, around 20,000 people in Japan are identified with bladder cancer, of whom around 8,000 males succumb to this medical condition. Bladder cancers can also be classified into two varieties: non-muscle-invasive cancers, which have a 5-12 months survival rate of 90 percent, and muscle-invasive cancers, which have terrible prognoses. The latter are generally dealt with with anticancer medicines such as cisplatin, but tend to emerge as chemoresistant and, hence, are able to spread to other organs such as the lungs and liver, as well as the bone.

In this study, human bladder cancer cells labeled with luciferase were inoculated into mice, making a xenograft bladder cancer mannequin. The principal bladder xenograft steadily grew and, after 45 days, metastatic tumors were detected within the lungs, liver and bone. Through microarray evaluation including more than 20,000 genes for the metastatic tumors, the researchers have found out a 3- to 25-fold increase in the metabolic enzyme aldo-keto reductase 1C1 (AKR1C1).

Additionally they found excessive levels of AKR1C1 in metastatic tumors which were removed from 25 cancer sufferers, proving that the phenomena which were found in the mice may also arise within the human body. Aside from anticancer medications, an inflammatory substance produced around the tumor, such as interleukin-1 beta, increased the enzyme levels.

The researchers also recognized initially that AKR1C1 enhances tumor-promoting activities and proved that the enzyme blocks the effectiveness of cisplatin and different anticancer medicines.

Flufenamic Acid

The researchers subsequently discovered that introducing flufenamic acid, an inhibitory factor for AKR1C1, into cancerous bladder cells has suppressed the cells’ invasive activities and has restored the efficacy of anticancer medicines. Flufenamic acid is a nonsteroid anti-inflammatory drug which has been used for treating common colds. Bene pigiausios auto dalys internetu automobiliams BMW, Audi, VW, Volvo, Renault ir t.t.

The researchers’ discovery is expected to foster the development of clinical exams aimed at bettering prognoses for bladder cancer patients. In these cutting-edge cancer therapies, highly-priced molecular-targeted medicinal drugs are used, thus striking a huge pressure on the medical economic climate and the state coffers.

According to Dr. Shinya Tanaka from the research team, This latest research could pave the way for medical institutions to use flufenamic acid — a much cheaper cold drug — which has unexpectedly been proven to be effective at fighting cancers.�

Can Chitosan in Crab Shells Promote Healing?

Dec 15, 2016

1714

A sugar from crab and shrimp shells, known as chitosan, when combines with nanomaterials, could lead to applications that can lead to bone and wound healing, a recent study shows. This finding, published in the journal Science, shows that nanomaterials can be combined with chitosan and can be used in various structures and applications that can greatly benefit the biomedical field, especially those that lead to the enhancement of bone regeneration, wound healing and targeted drug delivery.

Chitosan

Chitosan is a sugar that’s most commonly derived from shrimp and crab shell waste and is popular for its biocompatible, biodegradable, antibacterial, antifungal, analgesic and haemostatic properties. This makes it a primary candidate for a number of biomedical functions, if no longer for the truth that it has limited mechanical force. Researchers are working on setting up composites that combine chitosan with “nanofillers,” making the ensuing material stronger. An effective composite is one wherein the filler is well-dispersed inside the composite material, in order that it can interact strongly with chitosan.

Nanoparticles With Chitosan

Scientists are finding some success in combining bioactive glass nanoparticles with chitosan to improve synthetic bone grafts. Bioactive glass is a glass-ceramic biomaterial that binds well to physiological structures like bone. Bone cells have been observed to develop relatively swiftly and cover grafts made of bioactive glass and chitosan.

Graphene oxide has been used with chitosan to enhance “nanocarriers” that can provide medicinal drugs to target tissues, avoiding the negative effects that traditional medications can have on other tissues of the body.

Silver nanoparticles are now undergoing testing as nanofillers in blend with chitosan to improve wound dressings with antibacterial properties.

Additionally, haemoglobin (the protein in red blood cells that carries oxygen through the body), silver nanoparticles and graphene were mixed with chitosan to develop a biosensor that may observe hydrogen peroxide, a dangerous toxic substance from industries.

More studies are needed. Focus should be on making improvements to the dispersion of nanofillers inside the chitosan matrix, the researchers say. How these composite materials degrade is another subject that wishes additional pursuit. Also, more studies are needed to have an understanding of how these composite substances interact with host tissues in the body and whether these materials can be sterilized using conventional approaches so that they are able to be utilized in clinical applications. According to the researchers, The vast opportunities shown by these materials, allied with their incredible nanotechnology potential, are expected to revolutionize the biomedical field in the near future�.

Gut Bacteria Promotes Spinal Cord Injury Healing

Dec 14, 2016

2370

Scientists from the Ohio State University have discovered that spinal cord damage alters the kind of gut bacteria which are dwelling within the intestines and that these changes can exacerbate the extent of neurological harm and impair healing of function. The study, Gut dysbiosis impairs recovery after spinal cord injury� by Kristina A. Kigerl et al which was published in the October 2016 issue of The Journal of Experimental Medicine, suggests that counteracting these alterations with probiotics would aid sufferers’ restoration from spinal cord injuries.

Gut Bacteria

The trillions of bacteria that are living within the gastrointestinal tract are often called the gut microbiome. Disruption of this microbial community, or dysbiosis, occurs when non-harmful intestinal bacteria are depleted or overwhelmed by harmful inflammatory bacteria. Autoimmune illnesses such as multiple sclerosis, type I diabetes and rheumatoid arthritis were linked to dysbiosis, and it has been recently been implicated within the onset or development of neurological disorders, including autism, pain, depression, anxiousness, and stroke.

Spinal cord accidents have secondary effects or comorbidities, including loss of bowel movement control, which are more likely to cause dysbiosis. The authors remarked that if any changes in the gut microbiome occur, they would, in turn, have an effect on recuperation after spinal cord damage.

Spinal Cord Injury and Gut Microbiome

The researchers found out that spinal cord injury drastically altered the gut microbiome of mice, inducing the migration of intestinal bacteria into other tissues of the body and the activation of proinflammatory immune cells related to the intestines.

Mice that showed the most important changes in their intestinal microorganisms tended to recuperate poorly from their accidents. Indeed, when mice had been pre-treated with antibiotics to disrupt their gut microbiomes earlier than spinal cord injury, they showed higher phases of spinal inflammation and decreased healing. In contrast, when injured mice were given daily doses of probiotics to restore the phases of healthful intestinal microorganisms, they had much less spinal damage and regained more hindlimb action.

The probiotics, containing huge numbers of lactic acid-producing microorganisms, activated a sort of intestine-associated immune cells known as regulatory T cells that may suppress inflammation. These cells might prevent further injury to the spinal cord after harm. Additionally, the probiotic microorganism may speed up spinal cord healing via secreting molecules that enhance neuronal progress and function. According to the researchers, Either or both of these mechanisms could explain how post-injury disruption of the gut microbiome contributes to the pathology of spinal cord injuries and how probiotics block or reverse these effects�

They further added, Our data highlight a previously unappreciated role for the gut-central nervous system-immune axis in regulating recovery after spinal cord injury. No longer should ‘spinal-centric’ repair approaches dominate research or standards of clinical care for affected individuals.�

New Drug Palbociclib Changes Breast Cancer Treatment

Dec 13, 2016

2253

The huge global study, ABCSG 42/PALLAS, is presently investigating whether or not a drug (palbociclib) that is already displaying fine promise as remedy for metastasised breast cancer might also be highly successful in the treatment of the most common form of breast cancer: early-stage hormone-receptor-positive, HER2-negative breast cancer.

This study is being performed in the United States and in different nations such as Austria, Australia, Belgium and Spain. The lead investigator for all international locations outside USA is Michael Gnant, Head of the Breast Health Center at MedUni Vienna and Vienna General Hospital, Deputy Head of the Comprehensive Cancer Center (CCC) Vienna and President of the Austrian Breast & Colorectal Cancer Study Group (ABCSG). Over the next two years, as much as 500 patients from Austria can also be included within the study.

Breast Cancer Study

In Austria, there are around 5,200 new instances of breast cancer each year. The majority of these are women however some males are additionally affected. Around 75% of newly diagnosed breast cancers are of the hormone-receptor-positive type, that is to say their development is encouraged by the release of sex hormones.

In a large-scale worldwide study, ABCSG 42/PALLAS, researchers at the moment are investigating whether or not typical endocrine healing, in the form of a therapy that inhibits the creation of these hormones, may also be increased by the administration of the drug palbociclib. Palbociclib is a kinase inhibitor drug, an active agent that inhibits cell development and the division of cancer cells.

Michael Gnant, the head of this study outside US remarked, Palbociclib has already been licensed to treat metastasised breast cancer, where it is proving to be very successful. The drug has the potential to revolutionise the treatment of early-stage, hormone-receptor-positive breast cancer. Our aim is to extend progression-free survival and, in the long term, to achieve a permanent cure in the majority of patients.�

Internationally, it’s anticipated that 4,600 sufferers from 25 countries can be incorporated in this largest ever worldwide phase-III trial for patients with hormone-receptor-positive, early-stage breast cancer. Roughly half of those are being recruited in the US. Gnant remarked, Since the principal investigator is based here in Austria, with the focal point at the Comprehensive Cancer Center (CCC) of MedUni Vienna and Vienna General Hospital, we might manage to include up to 500 Austrian patients in the study, thereby giving them access to this new therapy.�

The ABCSG 42/PALLAS Study

The ABCSG 42/PALLAS study compares disease-free survival with typical endocrine therapy (at a minimum of 5 years) plus the drug palbociclib (2 years) in opposition to standard endocrine remedy alone (at least 5 years) in female and male breast cancer sufferers with ER-positive and HER-negative breast cancer and risk of recurrence Stage II or III. It’s taking position in an adjuvant setting, that’s to claim that all subjects have already had the tumour surgically removed.

Outside the United States, the study is currently being carried out in Austria, Australia, Belgium and Spain, with new trial centres joining always. For example, the Ethics Committee has already given an optimistic vote for Hungary. The recruiting phase must be completed by 2018; 309 sufferers have already been recruited global, eighty one of these from Austria.

The worldwide undertaking is being carried out alongside Alliance Foundation Trials (AFT), the Breast International Group (BIG) the German Breast Group (GBG), the National Surgical Adjuvant Breast and Bowel Project (NSABP), PrECOG from the Eastern Cooperative Oncology Group and Pfizer as industrial partner.

Colorectal Cancer Can Be Predicted Using Feces Fat

Dec 12, 2016

1747

Scientists have found out about a speedy, non-invasive method that could lead to the early detection of colorectal melanoma: feces fat. This is through making use of ultrasensitive and high-speed technology. In this method, the researchers identified a collection of molecules within the feces of mice that signifies the presence of precancerous polyps.

Scientists at Washington State University and Johns Hopkins Medical School have learned about a speedy, noninvasive approach that could result in the early analysis of colorectal cancer. Using ultrasensitive and fast technology, the researchers identified a collection of molecules in the feces of mice that signifies the presence of precancerous polyps. This “metabolic fingerprint” matches alterations in both mouse and human colon tumor tissues and suggests a new diagnostic instrument for the early detection of colorectal cancer in medical surroundings. The findings are published in the Journal of Proteome research.

Higher Screening Tools

Colorectal cancer is the second most common cancer around the world. Close to 1.4 million new cases were diagnosed in 2012, according to data provided by World Cancer Research Fund International. Colorectal cancer is the second main cause of cancer-related deaths in the US.

Although early detection is key to successful cure, most screening checks are limited in diagnostic capability or ease of application. Colonoscopy, for example, is a known lifesaver but is costly and unappealing to many individuals.

Decreasing the invasiveness of the approach would help. Williams mentioned that more persons would be inclined to provide a stool sample than endure a biopsy through a colonoscope. Moreover, colonoscopes can only extend a limited distance into the large intestine, possibly missing some polyps. According to Williams, “With our new test, it could be possible to diagnose cancer occurring throughout the entire colon.”

The researchers found out the molecular fingerprint for colon cancer by utilising a novel technology called ion mobility-mass spectrometry. IMMS is located in sensor devices internationally and is able to sniff out illicit medicines, chemical warfare and explosives in airports. One of the researchers, Hill, has been an innovator in the discipline for virtually 40 years.

In this case, IMMS was done with ultraperformance liquid chromatography.

The researchers first identified metabolic products from normal colon tissue in both humans and mice. IMMS can measure hundreds and hundreds of metabolites concurrently, like enzymes, fat, glucose and amino acids.

The scientists then compared this normal profile to that discovered in cancerous colon tissues from people and research mice with polyps of their colons that mimic these in humans.

In both instances, the scientists have found out that colon cancer induced enormous alterations in fat metabolism, notably for lipids and fatty acids. These abnormalities created a molecular fingerprint that was similar in humans and mice, mentioned Hill.

Diagnostic Changes Within The Feces

Hill and Williams then examined droppings from transgenic and control mice to look if the molecular fingerprint might be determined in feces as well.

Certainly IMMS detected many of the equal metabolic abnormalities seen within the earlier study and clearly distinguished between healthy mice and those with colorectal melanoma. Hill remarked, The feces was not exactly the same as the tissue samples, but it had a lot of similarities to the tissue. We found the lipids and fatty acids were changing — and there were also changes in the amino acids.�

Notably, a major classification of fat known as lysophospholipids changed dramatically, mentioned Williams. He added, These types of lipids are known to be important in the development of cancer and are particularly tied to colorectal cancer.�

“These forms of lipids are recognized to be most important within the development of melanoma and are peculiarly tied to colorectal cancer.” All these are encouraging to Hill and Williams as they seek for a good procedure to diagnose colorectal cancer within the early stages.

To know other medical breakthroughs, feel free to read our other articles on this site.

Natural Mulberry Compound Rutin Triggers Weight Loss

Dec 11, 2016

2074

According to new research published in the FASEB journal, rutin� a natural compound found in mulberries can activate the BAT (brown adipose tissue). BAT enhances our metabolism and helps in losing weight.

“The beneficial effects of rutin on BAT-mediated metabolic improvement have evoked a substantial interest in the potential treatment for obesity and its related diseases, such as diabetes,” mentioned Wan-Zhu Jin, Ph.D., a researcher involved in the work from the Institute of Zoology at the Chinese Academy of Sciences in Beijing, China. “In line with this idea, discovery of more safe and effective BAT activators is desired to deal with obesity and its related diseases.”

Rutin and Obesity

Genetically obese mice with diet-induced obesity were used as models for this research by Jin and his colleagues. Along with the usual diet, they were fed water containing supplemental rutin in the ratio of one milligram per millilitre. Treatment with rutin highly decreased adiposity, increased the energy expenditure and elevated glucose homeostasis in both models. Researchers discovered that rutin stabilizes SIRT1 (NAD-dependent deacetylase sirtuin-1) which leads to the hypoacetylation of PGC1. PGC1 protein is responsible for Tfam transactivation and finally increases mitochondrial number along with UCP1 activity in BAT1.

Rutin acts as a cold mimetic by triggering a SIRT1-PCG1-Tfam signalling cascade. This results in increasing mitochondrial number and UCP1 activity in BAT. Brown-like adipocyte formation is also induced by rutin in subcutaneous adipose tissue in both models.

Rutin in Humans

“Unlike hibernating animals, we humans have only a small spot of brown fat, and yet its importance in human metabolism has only recently come into view,” described Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal. “In this study, the philosophy of ancient Chinese medicine’s exploitation of plant materials has conjoined in the modern era with a very able physiology research team to evoke a promising lead.”

If you want to read more medical breakthroughs such as this, feel free to read our other articles on this site.

Written by: Lax Mariappan, Msc

Can 50-year-old Salmonella Treat Cancer?

Dec 10, 2016

1981

Salmonella has a distinct nature that makes bacteria penetrate through cell boundaries and multiply within its host. Currently, scientists have developed a non-toxic strain of Salmonella to penetrate and aim at cancer cells. Outcomes from this research might lead to promising new treatments that may effectively target and manage the spread of cancer.

The Centers for Disease Control stated that 48 million Americans contract food borne illnesses annually, with Salmonella being the main reason of illness. Salmonella has a distinct characteristic that allows the microorganism to penetrate through cell barriers and multiply inside its host. Now, scientists at the Cancer Research Center and the School of Missouri have developed a non-poisonous strain of Salmonella to penetrate and target cancerous cells. Reports from this study might lead to promising new therapies that actively target and manipulate the spread of cancer.

Salmonella and Cancer

“Salmonella strains have a natural preference for infiltrating and replicating within the cancer cells of a tumor, making the bacteria an ideal candidate for bacteriotherapy,” stated Robert Kazmierczak, a senior investigator on the Cancer Research Center and a post-doctoral fellow in the Division of Biological Sciences in the MU College of Arts and Science. “Bacteriotherapy is the use of live bacteria as therapy to treat a medical condition, like cancer.”

Kazmierczak and the team at the Cancer Research Center (CRC) developed CRC2631, a Salmonella strain that has been genetically altered to render the microorganism nontoxic and increase its natural capability to aim and destroy cancer cells — without harming normal, healthy cells. The Salmonella strain was administered directly into the circulatory system of mice with prostate cancer.

“We found that the mice tolerated the treatment well and when examined, their prostate tumors decreased by about 20 percent compared to the control group,” Kazmierczak mentioned. “One of the most remarkable aspects of Salmonella is its ability to target, spread and persist inside the tumor. We are taking advantage of this ability by using Salmonella to carry or generate effective chemotherapeutic drugs, concentrating them at and throughout the tumor. The goal of this treatment is to develop a bacterial vector that can destroy the tumor from the inside out and reduce the amount of side effects endured by patients with cancer.”

Sample CRC2631

CRC2631 is obtained from a Salmonella sample that was kept in a test tube at room temperature for more than 50 years. The sample came from the Demerec collection, a set of mutant traces of Salmonella gathered by geneticist Milisav Demerec and curated by Abraham Eisenstark, scientific director at the CRC and professor emeritus of biological sciences at MU. Intellectus stovyklos vaikams Kaune, Vilniuje bei angl? kalbos kursai Klaip?doje The compilation includes over 20,000 distinctive samples of Salmonella, with half of the samples housed at the Cancer Research Center where the researchers affiliated with MU focus on three areas of cancer research: early detection, targeted treatment and new, effective chemotherapy.

“The uniqueness of CRC2631 differentiates our Salmonella strains from other universities trying to achieve the same goal; it is one of a kind,” Eisenstark added. “The strain of Salmonella we are using is essential to the success of our study.”

The study, “Salmonella Bacterial Monotherapy Reduces Autochthonous Prostate Tumor Burden in the TRAMP Mouse Model,” was recently published in PLOS ONE.

To read other interesting breakthroughs in medicine, feel free to read our other articles on this site.

Written by Lax Mariappan, Msc

Gene Therapy Ointment Prevents Diabetic Neuropathy

Dec 9, 2016

2066

A new dermatological remedy known as a gene therapy ointment being tested by Northwestern Medicine scientists ought to prevent and maybe even reverse the neuropathy. This can help around 25% of diabetics who have neuropathy.

In a study posted in Molecular Pain journal, Northwestern Medicine researchers confirmed that depleting a chemical referred to as GM3 thru genetic modification avoided the development of neuropathy in obese diabetic mice.

Gene Remedy Ointment

The researchers are now making use of a gene therapy ointment to burn up GM3 and GM3 synthase, which is the enzyme that makes GM3. The desire is that this GM3-depleting ointment, applied just to the footpad of diabetic mice, will save you or, even reverse the present neuropathy. According to Dr. Amy Paller, the Walter J. Hamlin professor of dermatology at Northwestern University Feinberg School of Medicine and director of Northwestern’s Skin Disease Research Center, We have such terrible treatments right now for the neuropathy of diabetes. We’re basically only treating the pain. This is a novel pathogenesis-based approach that looks at what’s causing the neuropathy and reverses that instead of just treating the pain.�

The kind of neuropathy the researchers are trying to treat is going past the typical numbness some patients with neuropathy revel in, stated first author Dr. Daniela Menichella, assistant professor of neurology at Feinberg whose cognizance is the clinical care and laboratory-based studies of diabetic neuropathy. She remarked, It’s not that you just don’t have sensation in your feet. You have shooting pain, which is the unbearable part. Pain is a debilitating affliction and one of the worst complications of diabetes.�

Leading as much as this treatment, the researchers had observed that ordinary diabetic mice had a lot extra GM3 and GM3 synthase in their nerves as compared to regular mice. They discovered the equal aspect to be true inside the pores and skin of mice and human beings with diabetes.

The scientists then compared the appearance and function of the nerves in mice in which GM3 was depleted with the aid of genetic manipulation. In routine diabetic mouse skin, the nerves had actually disappeared from degeneration, but they have been truly normal in appearance within the GM3-depleted mice, even though the mice had been as obese and diabetic like the usual diabetic mice.

To check pain response, researchers used filaments of growing force to touch the paws of mice and then timed how long it took for the mice to withdraw their paw from the pain stimulation. According to Paller, The routine diabetic mice had nerve changes that intensified their pain sensation, and they experienced a lot of pain with just a light touch. When we rescued them by depleting their GM3, they didn’t withdraw their feet (suggesting pain) any more quickly than the mice without diabetes.�

Based totally on these discoveries, the researchers have made the method superior to domestically depleting GM3 within the feet with the new ointment. Paller further remarked, If the studies look promising in mice, our long-term goal would be to further test safety and advance to human clinical trials to prevent and/or reverse the development of diabetic neuropathy�.

High Factor Sunscreen Can Decrease Skin Cancer Risk

Dec 6, 2016

1758

A large study published by the department of Biostatistics on the University of Oslo within the Journal of Clinical Oncology observed that using high factor sunscreen as compared with low factor sunscreen can decrease the risk of cancer by 33%.

Using Sunscreen Does Not Guarantee Safety

In this study, sunscreen users pronounced more sunburn, extra sunbathing vacations and use of sunbeds than folks who had not used sunscreen. As a result no-sunscreen users had a decrease hazard of growing melanoma than folks who used low factor sunscreen.

The Department of Biostatistics with the Faculty of Medicine on the University of Oslo have discovered that sunscreen with an adequate factor can reduce the chance of cancer by more than 30 percent compared with low factor sunscreen.

Melanoma is the cancer with the strongest increase in incidence in the last decade, and the incidence rates have never been as high as in 2014. Now there are about 2,000 new cases of melanoma every year in Norway.

The Ambiguity Of Sunscreen Use

Earlier research has blended consequences; some studies discovered slightly elevated risks of melanoma among sunscreen users. According to Reza Ghiasvand, a PhD candidate at The Department of Biostatistics and a member of the research group Epidemiological Studies of Lifestyle and Chronic Diseases�, The explanation for this paradox is that some people use sunscreen to prolong sun exposure and acquire suntan. Moreover, many people don’t apply the proper amount of sunscreen, forget to reapply and missed to apply on all exposed areas resulting in sunburn and increased risk of melanoma. We found that those who used sunscreen with a factor higher than 15 had a 33% lower risk of melanoma compared with those using sunscreen with a low factor.�

The study group gained access to data from the NOWAC study (https://site.uit.no/nowac/) merged with data from the Cancer Registry of Norway. The study followed over 140,000 Norwegian women for an average of ten years.

Prev 1...333435...76 Next

Page 34 of 76